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1. Introduction 
Ulcerative colitis (UC) is an idiopathic chronic inflammatory disease of the colon and 
rectum, characterized by mucosal inflammation and typically presenting with bloody 
diarrhea. Crohn’s disease is characterized by transmural inflammation of the gut wall and 
can affect any part of the tubular gastrointestinal tract. Although the underlying etiology 
and exact pathogenesis remain fully unclarified, current hypothesis favors dysregulation of 
gastrointestinal immune system in genetically predisposed individuals [1]. Extra-intestinal 
manifestations of inflammatory bowel disease (IBD) are common, ensuing in approximately 
40% of patients [2], many of which are postulated to be associated with autoimmune 
mechanisms [3]. Renal manifestations associated with IBD, however, have rarely been 
reported. Sulfasalazine reaches the colon intact, where it is metabolized to 5-aminosalicylic 
acid (5-ASA, mesalazine, mesalamine) and a sulfapyridine moiety. It is therefore used for 
colonic disease, either as initial therapy or to maintain remission. Adverse effects are mainly 
caused by the sulfapyridine moiety and include headache, vomiting, and abdominal pain. A 
reduction in dose is usually beneficial. Newer 5-ASA preparations lack the sulfa moiety of 
sulfasalazine and are associated with fewer side effects. Mesalamines are slow-release 
formulae of 5-ASA and are effective as a primary tool for initial and maintenance therapy of 
IBD. Rare hypertensitivity reactions occur and include pneumonitis, pancreatitis, and 
hepatitis. Recently, several case reports have been published suggesting an association 
between the use of 5-ASA and the development of chronic tubulointerstitial nephritis in 
patients with IBD [4, 5]. Because of adverse effects of these agents, differentiation of renal 
complications subtending these therapies from the true extraintestinal manifestations of IBD 
involves much difficulty. 
In this review, we note the drugs including 5-ASA associated nephrotoxicity and also show 
case reports of UC related nephritis.  
2. Drugs of the treatment for IBD associated nephrotoxicity 
2.1 Epidemiology of nephrotoxicity in IBD 
Sulfasalazine has been used in the treatment of IBD, both for UC and for Crohn’s disease. 
Newer 5-ASA preparations lack the sulfa moiety of sulfasalazine and are associated with 
fewer side effects. Mesalamines are slow-release formulae of 5-ASA and are effective as a 
primary tool for initial and maintenance therapy of IBD. Azad Khan et al. studied the 
therapeutic activity of the component parts of sulfasalazine and found that 5-ASA was the 
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therapeutically active component of the drug [6]. In moderate active UC, both sulfasalazine 
and 5-ASA have proven to be effective in inducing and maintaining clinical remission. 
However, a number of cases have shown the 5-ASA related toxicity [7, 8]. In particular, 
nephrotoxicity has been described in some patients with IBD treated with 5-ASA [7, 8]. In 
this respect, both acetylsalicylic acid and phenacetin, which have been implicated in the 
occurrence of nonsteroidal antiinflammatory drug-induced nephropathy, share structural 
similarities with 5-ASA [9, 10]. Furthermore, previous studies reported that 5-ASA may 
cause injuries to tubular epithelial cells in animals when fed in high doses [9, 10]. The actual 
incidence of nephrotoxicity in IBD patients with 5-ASA therapy has not been determined, 
but it has been suggested that renal impairment may occur in up to 1% of patients treated 
with 5-ASA. A recent prospective study revealed that renal impairment was observed in 2-
3% of IBD patients with and without concomitant 5-ASA treatment [11]. More recently, a 
case-control analysis found that IBD patients treated with 5-ASA had an increased risk of 
renal disease [12]. However, after adjustment for several factors and variables, the risk of 5-
ASA users was comparable to controls. This study found that IBD patients without 5-ASA 
also had increased risk of renal disease. Taken together, although users of 5-ASA may have 
an increased risk of renal disease, it may be partly attributable to the underlying disease 
[12].  
2.2 Monitoring markers in IBD 
Microalbuminuria has been demonstrated to be present in the majority of IBD patients, and 
it seems to be related to disease activity. However, other studies have shown that 
microalbuminuria is not present in patients with IBD [13]. Some authors have concluded 
that an increased prevalence of tubular proteinuria may be attributed to high doses of 5-
ASA [14]. Nevertheless, differences among these studies may be related to differences in 
disease activity of IBD. Taken together, it is important to conduct a systematic evaluation of 
the effect of 5-ASA treatment on renal function in patients with IBD. 
5-ASA treatment-related nephrotoxicity is reported most often within the first 12 months, 
but also delayed presentation after several years has been observed. Thus, regular 
monitoring of renal function should be performed during the therapy. 
Several attempts have been made to measure early signs of renal impairment in patients 
with IBD treated with 5-ASA using sensitive markers of glomerular and tubular 
dysfunction. Riley et al. found that the incidence of elevated urinary markers such as N-
acetyl-D-glucosamidase is low in patients with quiescent UC, which is independent of the 
dose and duration of 5-ASA treatment [15]. When renal damage occurs, its presence is 
unlikely to be detected by urinalysis in its early remediable stages. Although tubular 
enzymuria may be a more sensitive and specific marker of renal damage, it is not yet 
available as a screening method and the correlation between the several urinary markers of 
renal damage and 5-ASA treatment remains unproven. These limitations emphasize the 
importance of monitoring serum creatinine in patients with IBD treated with 5-ASA. 
2.3 The incidence of renal disease in IBD 
It has been suggested that mesalazine may induce renal impairment more frequently than 
sulfasalazine [16]. In an analysis of spontaneous reports of adverse events in the UK, 5-ASA-
related nephrotoxicity seemed more frequent in mesalazine-treated patients compared with 
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sulfasalazine-treated patients [17]. Recently, data from the UK General Practice Research 
Database were used to estimate the incidence of renal disease in adult patients with IBD, 
and mesalazine and sulfasalazine users had comparable risks of nephrotoxicity (0.17 versus 
0.29 cases per 100 person-years, respectively) [12]. It can be conluded that the nephrotoxicity 
potential of mesalazine and sulfasalazine seems to be similar, and,even if differences exist, 
they are probably small. Mesalazine should be withdrawn when renal impairment manifests 
in a patient with IBD in whom no other cause can be readily identified. If withdrawal of 5-
ASA treatment does not result in a fall in serum creatinine, then the patient should be 
referred for consideration of renal biopsy to make sure whether interstitial nephritis or 
glomerulonephritis associated with IBD is the cause of the persistent impaired renal 
function.  
2.4 Treatment for renal impairment in IBD 
Steroids and azathioprine have been used in patients with renal impairment due to 
mesalazine-associated interstitial nephritis, but the evidence for beneficial roles is anecdotal 
and uncontrolled. Partial improvement or even complete recovery of renal function after 
steroid therapy has been reported by several authors. However, other studies have been 
unable to demonstrate a beneficial effect of these immunosuppressive drugs. Nevertheless, 
it has been suggested that a trial of high-dose steroid (60 mg/day or 1 mg day/kg for up to 
3 months) may be recommended in patients whose renal function does not respond to drug 
withdrawal alone [7]. Although most case reports indicate reversibility after cessation of the 
drug, in some cases permanent clinical kidney dysfunction has been observed. Thus, it has 
been calculated that 10% of the patients with 5-ASA nephrotoxicity will develop end-stage 
renal disease [5]. 
3. Case reports of UC related nephritis 
3.1 ANCA related nephritis  
UC is typically associated with antineutrophil cytoplasmic antibodies of perinuclear type (p-
ANCA). These antibodies are not usually considered to carry potential for the development 
of systemic vasculitis as they lack specificity for proteinase 3 (PR3) or myeloperoxidase 
(MPO). ANCA can be detected in sera from patients with a wide variety of inflammatory 
diseases including UC. In one study of 50 patients with UC, 54% were shown to be either p-
ANCA or c-ANCA positive but none of these antibodies reacted with PR3 or MPO [18]. In 
another study, ANCA-positive patients with UC were followed for a year during which no 
evidence of glomerulonephritis was found [19]. 
3.2 IgA nephropathy 
UC may be associated with a number of extraintestinal complications, involving almost 
any organ system. The organs most commonly involved include the skin, joints, biliary 
tract and eyes [3, 20]. However, renal and genitourinary tract manifestations are quite 
rare, particularly glomerulonephritis. They reported that a patient of IgA nephropathy 
with UC and chronic intermittent episodes of indolent macrohematuria [21]. IgA 
nephropathy can be primary in most cases or secondary but is rarely associated with UC 
[22, 23]. Altered T-helper cells’ function might be the initial common derangement of both 
UC and IgA nephropathy [24, 25]. In IgA nephropathy such alteration in CD4-positive T 
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cells causes a nonspecific stimulus on plasma cells in the bone marrow to secrete 
polymeric IgA1 into the circulation [26, 27] and of IgG1 and IgG3 in UC [28, 29] 
culminating in both cases with a common state of local cytokine secretion and tissue 
inflammation. 
3.3 UC related interstitial nephritis 
Lately, we reported a patient with UC who has developed acute interstitial nephritis and the 
subsequent renal failure following a long pause of the treatment with mesalazine [30]. In 
this case, we observed progressive decline in renal function in a patient with UC. Although 
the patient exhibited stable levels of serum Cr during the 3 year period after the treatment 
with mesalazine and sulfapyridine was discontinued, he developed severe interstitial 
nephritis associated with moderately active UC (Figure 1). His renal biopsy samples showed 
evidence of severe active tubulointerstitial nephritis along with intense renal interstitial 
infiltration of CD3-positive T cells (Figure 2). Colonic fiberscopic examination also revealed 
moderate UC activity and the mucosal infiltration of CD3-positive cells, thus suggesting the 
common immune mechanism possibly mediated by T-cell dysregulation. Since the patient 
had not used any nephrotoxic agent for at least three years, it was reasonable to conclude  
 
 
Fig. 1. UC related interstitial nephritis (PAS staining) 
www.intechopen.com
 
Nephritis Associated with Ulcerative Colitis 
 
275 
 
Fig. 2. Intense interstitial infiltration of CD3-positive T cells was detected in the kidney 
(Upper). The infiltration of CD3-positive cells into the intestinal mucosa was also observed 
(Lower) 
that the main precipitating cause of the progression of renal injury during the medication-
free period is attributable to the disease activity of UC per se, rather than the flare-up of the 
reminiscence of mesalazine effect.    
Drug-induced nephropathy constitutes a critical problem that precludes the continued use 
of the agent. Nephrotoxicity has been described in patients with IBD treated with 5-ASA [4, 
5]. In the literature survey, 5-ASA-associated nephrotoxicity is reported most often within 
the first 12 months from the initiation of the drug [31], but delayed presentation has also 
been shown rarely, with the onset of the renal manifestation after several years of the 
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treatment [32, 33]. In most of their reports, however, 5-ASA was given continuously during 
the latent period. In our case, by contrast, nephrotoxic agents, including mesalazine or 
sulfapyridine, were discontinued for at least three years, during which renal function 
remained relatively stable. Collectively, it appears unlikely that the aggravating process 
after the cessation of the drugs is associated with the direct nephrotoxic effect of these 
agents.  
 
 
Fig. 3. Colonic fiberscopic findings unveiled moderate UC activity  
Since IBD is acknowledged as autoimmune disease affecting multiple extraintestinal 
organs, it is possible that the kidney is a target organ for the UC-associated systemic 
injury. Indeed, several types of kidney disease have been documented, including 
glomerulonephritis, membranous nephropathy and nephrotic syndrome as rare extra-
intestinal manifestations of IBD [34-35]. In contrast to glomerular disease, 
tubulointerstitial nephritis unrelated to nephrotoxic agents has rarely been reported 
hitherto [36]. Of note, it has been shown that a substantial number of patients manifest 
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pathological enzymuria [37]. Furthermore, a strong correlation between disease activity 
and tubular proteinuria has been reported in IBD [38]. In our recent case report, the 
patient shows moderate UC activity (Figure 3) and progressive course of interstitial 
nephritis with no nephrotoxic agent given during the antecedent 3-year period. Although 
there reported one case showing that the renal injury does not parallel the activity of IBD 
[33], the absence of other aggravating factors rather favors the recognition of the UC 
activity as a precipitating mechanism in this case.   
Link between IBD and kidney disease merits comment. As shown in the present case, the 
kidney constitutes a target organ involved in the UC-induced systemic disorders. 
Furthermore, the kidney, where various drugs and their metabolites are condensed in situ 
and excreted in the urine, is susceptible to the nephrotoxicity of these agents. Of more 
clinical importance, the present case sheds light on the kidney as an organ affected in  
IBD albeit low incidence reported so far. To the extent that the kidney disease  
contributes substantially to the development of cardiovascular events, our observation  
would emphasize the need for increasing awareness of the kidney in the management of 
IBD.  
4. Conclusion 
A large number of biological agents as well as many biochemical substances and molecules 
specifically for the medical treatment of patients with IBD, have been developed. 
Sulfasalazine has been used in the treatment of IBD, both for UC and for Crohn’s disease. 
Mesalamines are slow-release formulae of 5-ASA and are effective as a primary tool for 
initial and maintenance therapy of IBD. Recently, several case reports have been published 
suggesting an association between the use of 5-ASA and the development of chronic 
tubulointerstitial nephritis in patients with IBD. Because of adverse effects of these agents, 
differentiation of renal complications subtending these therapies from the true 
extraintestinal manifestations of IBD involves much difficulty. Since IBD is acknowledged as 
autoimmune disease affecting multiple extraintestinal organs, it is possible that the kidney is a 
target organ for the UC-associated systemic injury. Indeed, several types of kidney disease 
have been documented, including glomerulonephritis, membranous nephropathy and 
nephrotic syndrome as rare extra-intestinal manifestations of IBD. We also reported the case 
of acute interstitial nephritis associated with UC. As noted in our case report, we assume 
that the renal manifestation is attributed to intrinsic disease process of the UC-mediated 
immune dysregulation, and emphasize the need for the pathophysiological evaluation of the 
intestine and other organs in clinical situations. 
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